$1.61
+0.04 (+2.55%)
Open$1.50
Previous Close$1.57
Day High$1.70
Day Low$1.48
52W High$3.56
52W Low$1.27
Volume—
Avg Volume152.6K
Market Cap68.99M
P/E Ratio—
EPS$-1.88
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+2,546.6% upside
Current
$1.61
$1.61
Target
$42.61
$42.61
$22.54
$42.61 avg
$49.20
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 27.49M | 26.17M | 29.17M |
| Net Income | -6,413,122 | -6,638,758 | -7,979,028 |
| Profit Margin | -23.3% | -25.4% | -27.4% |
| EBITDA | -10,041,478 | -10,799,684 | -11,152,703 |
| Free Cash Flow | -6,132,912 | -6,792,749 | -5,207,622 |
| Rev Growth | +12.4% | +6.3% | +17.3% |
| Debt/Equity | 0.29 | 0.25 | 0.27 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |